Head-to-head evidence
Aripiprazole (Abilify Maintena) vs Brexpiprazole long-acting injection (Kelun)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify Maintena)
Marketed by Otsuka Holdings and partners
NCT00706654 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Brexpiprazole long-acting injection (Kelun)
Developed by Sichuan Kelun Pharmaceutical Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify Maintena)'s landscape · Brexpiprazole long-acting injection (Kelun)'s landscape